抗糖尿病药物可以通过Cdk5抑制与肥胖相关的PPARgamma的酸化
Jang Hyun Choi1, Alexander S Banks, Jennifer L Estall
1Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Nature
|July 24, 2010
概括
高脂肪饮食激活Cdk5,在脂肪组织中化PPARgamma. 这会扰乱基因表达,并降低阿迪波内克丁,导致胰岛素抵抗. 阻止这种酸化可能会提供新的抗糖尿病治疗方法.
科学领域:
- 代谢性疾病研究研究.
- 分子内分泌学分子内分泌学
- 脂肪组织生物学 脂肪组织生物学
背景情况:
- 肥胖与胰岛素耐药性和脂肪细胞基因表达的改变有关.
- 氧酶增殖器激活受体玛 (PPARgamma) 是脂肪细胞功能的一个关键调节器.
- 特定蛋白质修饰在与肥胖相关的代谢功能障碍中的作用是一个活跃的研究领域.
研究的目的:
- 调查循环林依赖激酶5 (Cdk5) 在肥胖引起的代谢变化中的作用.
- 确定Cdk5对脂肪组织中PPARgamma活性和基因表达的影响.
- 探索针对Cdk5介导的PPARgamma酸化对抗胰岛素的治疗潜力.
主要方法:
- 在使用高脂肪食的小鼠中诱导肥胖.
- 在脂肪组织中分析蛋白质激酶Cdk5激活和PPARgamma酸化.
- 基因表达分析以识别失调的基因,包括adiponectin.
- 在体外和体内实验中使用抗糖尿病PPARgamma连接剂 (罗斯伊格利塔,MRL24).
主要成果:
- 高脂肪食激活了脂肪组织中的Cdk5,导致PPARgamma酸化在血清273.
- PPARgamma酸化并没有影响脂肪生成能力,但影响了与肥胖相关的基因调节失调,包括减少脂肪素.
- 抗糖尿病PPARgamma连接物阻断了Cdk5介导的PPARgamma酸化,而不依赖于转录激应.
- 罗西格利塔抑制PPARgamma酸化与其在肥胖患者中的抗糖尿病作用相关.
结论:
- 通过Cdk5介导的PPARgamma的酸化与胰岛素抵抗的发病有关.
- 准Cdk5介导的PPARgamma修饰为胰岛素抵抗提供了一个新的治疗策略.
- 开发下一代抗糖尿病药物可以专注于调节PPAR玛酸化.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
cAMP-dependent Protein Kinase Pathways
7.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K


